ADC Therapeutics' Zynlonta gains US approval for r/r DLBCL

24 April 2021

On Friday, Swiss antibody-drug conjugate specialist ADC Therapeutics (NYSE: ADCT) saw its shares gain almost 5% to $24.40 after-hours, as it revealed that the US Food and Drug Administration has granted accelerated approval for Zynlonta (loncastuximab tesirine-lpyl).

The drug is cleared for the treatment of adult patients with relapsed or refractory (r/r) large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified (NOS), DLBCL arising from low grade lymphoma and high-grade B-cell lymphoma.

Zynlonta is the first and only CD19-targeted antibody drug conjugate (ADC) for the treatment of r/r DLBCL. Zynlonta fills a significant unmet need in r/r DLBCL in heavily pre-treated patients with difficult to treat disease and has the potential to become the standard of care in 3L+ DLBCL. The 3L+ DLBCL total market consists of 10,500 patients in the USA/EU5 and represents a $1 billion+ opportunity, according to the company.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK